Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Sleep loss induces cholesterol-associated myelin dysfunction

The increasing prevalence of sleep deprivation poses a public health challenge in modern society. Manifestations of reduced alertness, such as slowed reaction times and increased errors, are well-documented behavioral indicators of sleep loss (SL). Yet, the biological consequences of sleep deprivation and their role in behavioral impairment remain elusive. Our study reveals significant effects of sleep deprivation on myelin integrity. As a result, we identify increased conduction delays in nerve signal propagation, hindered interhemispheric synchronization, and impaired cognitive and motor performance associated with SL. By profiling oligodendrocyte transcriptome and lipidome, we observe SL-induced endoplasmic reticulum stress and lipid metabolism dysregulation, particularly affecting cholesterol homeostasis.

New lab technique can reverse chemical process linked with Alzheimer’s disease

An Oregon State University scientist and a team of undergraduate students have uncovered real-time insights into a chemical process linked with Alzheimer’s disease, paving the way toward better drug designs. The researchers used a molecule measuring technique to observe in a laboratory setting how certain metals can promote the protein clumping that leads to the blocked neural pathways associated with Alzheimer’s. Led by Marilyn Rampersad Mackiewicz, associate professor of chemistry in the OSU College of Science, the research team also watched molecules known as chelators disrupt or reverse the clumping. The findings are published in ACS Omega.

Alzheimer’s disease is the most common form of dementia, a chronic condition of impaired cognitive function that affects large numbers of older adults and their loved ones. According to the Centers for Disease Control and Prevention, Alzheimer’s is the sixth-leading cause of death for people age 65 and older.

In Alzheimer’s patients, aggregations of amyloid-beta proteins interrupt brain cells’ ability to communicate with each other. The brain needs certain metals to work properly, but problems arise when the metals are present in unbalanced quantities.

Abstract: Birt-Hogg-Dubé syndrome is largely characterized by pulmonary cysts, but disease models for this lung phenotype are lacking

Here, Elizabeth P. Henske report mTORC1 hyperactivation in cystic lungs from patients and validate its role in lung cyst formation using a novel pre-clinical model:

The figure shows lung mesenchymal and epithelial cell differentiation.


1Division of Pulmonary, Critical Care and Sleep Medicine; Department of Internal Medicine; University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

2The Saban Research Institute, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.

3Division of Pulmonary and Critical Care Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, USA.

‘It seemed to defy the laws of physics’: The everlasting ‘memory crystals’ that could slash data centre emissions

In the face of rising emissions from data centres, researchers are turning to micro-explosions in glass, and using DNA to solve big data’s big problem.

Mathematicians make a breakthrough on 2,000-year-old problem of curves

From the article:

“A Rule for Every Curve”

That’s where the new proof comes in. Its authors present a formula that can be applied to any curve in the mathematical universe, whatever its degree. It doesn’t say precisely how many rational points that curve has, but it gives an upper limit on what that number can be.

Previous formulas of this kind either didn’t apply to all curves or depended on the specific equation used to define them. The new formula is something mathematicians have hoped for since Faltings’s proof, a “uniform” statement that applies to all curves without depending on the coefficients in their equations. “This one statement gives us a broad sweep of understanding,” Mazur says.

It depends on only two things. The first is the degree of the polynomial that defines the curve—the higher the degree is, the weaker the statement becomes. The second thing the formula depends on is called the “Jacobian variety,” a special surface that can be constructed from any curve. Jacobian varieties are interesting in their own right, and the formula offers a tantalizing path for studying them as well.”


Since ancient Greece, researchers have tried to isolate special rational points on curves. Now they have the first ever formula that applies uniformly to all curves.

FDA Greenlights Life Biosciences’ Human Study, Setting Up Pivotal Test for Aging Theory from Harvard’s David Sinclair

…Life Biosciences, a biotech company co-founded by Sinclair, received the FDA’s approval to begin a human trial testing its gene therapy based on the Information Theory of Aging. The gene therapy is designed to rewind the clock and restore the function of dying cells…

…Life Biosciences’ gene therapy has been under development for quite a while. In the 1990s, David Sinclair first contended that the deterioration and loss of epigenetic information—chemical tagging patterns on DNA that regulate which genes are turned on and off—plays an important role in driving aging. Sinclair subsequently dubbed this contention the Information Theory of Aging. Fast forward to the present day, and Life Biosciences has produced a gene therapy that delivers three proteins, which Sinclair’s laboratory helped establish, to reset epigenetic information to a more youthful state.

‘It’s extremely exciting,’ Sinclair told Endpoints News. ‘It’s been over 30 years to get to this point, and we’re about to learn if all of that work is going to come to fruition this year.’


The FDA has greenlighted Life Biosciences’ first human trial testing whether their gene therapy can confer a near-total rejuvenating reset of cells.

Virus-based therapy boosts anti-cancer immune responses to brain cancer

A team led by investigators has shown that a single injection of an oncolytic virus—a genetically modified virus that selectively infects and destroys cancer cells—can recruit immune cells to penetrate and persist deep within brain tumors. The research, which is published in Cell, provides details on how this therapy prolonged survival in patients with glioblastoma, the most common and malignant primary brain tumor, in a recent clinical trial.

The oncolytic virus used in the team’s trial is made from a herpes simplex virus genetically altered so it can only make copies of itself in glioblastoma cells and not normal healthy cells. The virus spreads to a glioblastoma cell, kills it, and then makes a copy of itself that spreads again to another glioblastoma cell. Infection of cells with the virus also triggers an immune response. In the phase 1 trial of 41 patients with recurrent glioblastoma, the oncolytic virus treatment extended survival compared to historically reported survival, especially among those with pre-existing viral antibodies.

In their Cell study, the investigators examined the extent of this immune response in clinical trial participants. Their analysis revealed that the treatment induced long-term infiltration of immune T cells into patients’ tumors. Closer proximity of cytotoxic T cells with dying brain tumor cells was associated with longer patient survival after treatment. The therapy also expanded pre-existing T cells in the brain. ScienceMission sciencenewshighlights.

Rapid Evolution of Complex Multi-mutant Proteins

The researchers developed MULTI-evolve, a framework for efficient protein evolution that applies machine learning models trained on datasets of ~200 variants focused specifically on pairs of function-enhancing mutations.

Published in Science, this work represents the first lab-in-the-loop framework for biological design, where computational prediction and experimental design are tightly integrated from the outset, reflecting our broader investment in AI-guided research.

Our insight was to focus on quality over quantity. First identify ~15–20 function-enhancing mutations (using protein language models or experimental screens), then systematically test all pairwise combinations of those beneficial mutations. This generates ~100–200 measurements, and every one is informative for learning beneficial epistatic interactions.

We validated this computationally using 12 existing protein datasets from published studies. Training neural networks on only the single and double mutants, we found models could accurately predict complex multi-mutants (variants with 3–12 mutations) across all 12 diverse protein families. This result held even when we reduced training data to just 10% of what was available.

Training on double mutants works because they reveal epistasis. A double mutant might perform better than the sum of its parts (synergy), worse than expected (antagonism), or exactly as predicted (additivity). These pairwise interaction patterns teach models the rules for how mutations combine, enabling extrapolation to predict which 5-, 6-, or 7-mutation combinations will work synergistically.

We then applied MULTI-evolve to three new proteins: APEX (up to 256-fold improvement over wild-type, 4.8-fold beyond already-optimized APEX2), dCasRx for trans-splicing (up to 9.8-fold improvement), and an anti-CD122 antibody (2.7-fold binding improvement to 1.0 nM, 6.5-fold expression increase). For dCasRx, we started with a deep mutational scan of 11,000 variants, extracted only the function-enhancing mutations, and tested their pairwise combinations—demonstrating the value of strategic data curation for efficient engineering.

Each required experimentally testing only ~100–200 variants in a single round to train models that accurately predicted complex multi-mutants, compressing what traditionally takes 5–10 iterative cycles over many months into weeks. Science Mission sciencenewshighlights.

At our upcoming conference

we are thrilled to host Joscha Bach at Future Day 2026 – he is a leading voice in cognitive architectures and the founding director of the California Institute for Machine Consciousness. Bach’s talks are famous for being mind-bending journeys that challenge fundamental assumptions about reality and agency. In his upcoming session, he will dive into the Machine Consciousness Hypothesis, offering a glimpse into how we might one day create truly sentient digital minds.


Joscha Bach – The Machine Consciousness Hypothesis.

What if our consciousness is not a ‘thing’ we have, but a simulation our brain runs to make sense of itself?

We’ve Been Invaded By Aliens… Now What?

If aliens invaded, how would humanity respond? From planetary defense and space warfare to unexpected diplomatic twists, we’ll explore the strategies, technologies, and scenarios that could decide our fate.

Watch my exclusive video Post-Consciousness Civilizations: https://nebula.tv/videos/isaacarthur–
Get Nebula using my link for 40% off an annual subscription: https://go.nebula.tv/isaacarthur.
Get a Lifetime Membership to Nebula for only $300: https://go.nebula.tv/lifetime?ref=isa
Use the link gift.nebula.tv/isaacarthur to give a year of Nebula to a friend for just $30.

Visit our Website: http://www.isaacarthur.net.
Join Nebula: https://go.nebula.tv/isaacarthur.
Support us on Patreon: / isaacarthur.
Support us on Subscribestar: https://www.subscribestar.com/isaac-a
Facebook Group: / 1583992725237264
Reddit: / isaacarthur.
Twitter: / isaac_a_arthur on Twitter and RT our future content.
SFIA Discord Server: / discord.
Credits:
We’ve Been Invaded By Aliens… Now What?
Episode 494a; April 13, 2025
Written, Produced & Narrated by: Isaac Arthur.
Edited by: Ludwig Luska.
Graphics: Jeremy Jozwik, Ken York YD Visual, Legiontech Studios.
Select imagery/video supplied by Getty Images.
Music Courtesy of Epidemic Sound http://epidemicsound.com/creator.
Sergey Cheremisinov, \

/* */